These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 15767024)
1. Clinical heterogeneity of drug hypersensitivity. Roujeau JC Toxicology; 2005 Apr; 209(2):123-9. PubMed ID: 15767024 [TBL] [Abstract][Full Text] [Related]
2. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. Mockenhaupt M J Dtsch Dermatol Ges; 2009 Feb; 7(2):142-60; quiz 161-2. PubMed ID: 19371237 [TBL] [Abstract][Full Text] [Related]
3. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Wolf R; Matz H; Marcos B; Orion E Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547 [TBL] [Abstract][Full Text] [Related]
4. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378 [TBL] [Abstract][Full Text] [Related]
5. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Walsh SA; Creamer D Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513 [TBL] [Abstract][Full Text] [Related]
6. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J; Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Ding WY; Lee CK; Choon SE Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508 [TBL] [Abstract][Full Text] [Related]
8. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Ghislain PD; Roujeau JC Dermatol Online J; 2002 Jun; 8(1):5. PubMed ID: 12165215 [TBL] [Abstract][Full Text] [Related]
9. Phenotype standardization for immune-mediated drug-induced skin injury. Pirmohamed M; Friedmann PS; Molokhia M; Loke YK; Smith C; Phillips E; La Grenade L; Carleton B; Papaluca-Amati M; Demoly P; Shear NH Clin Pharmacol Ther; 2011 Jun; 89(6):896-901. PubMed ID: 21562486 [TBL] [Abstract][Full Text] [Related]
17. DRESS syndrome with mild manifestations as a diagnostic and therapeutic problem: case report. Artuković M; Kustelega J; Lugović-Mihić L Acta Clin Croat; 2010 Dec; 49(4):479-84. PubMed ID: 21830461 [TBL] [Abstract][Full Text] [Related]
18. Recognition and management of severe cutaneous drug reactions. Knowles SR; Shear NH Dermatol Clin; 2007 Apr; 25(2):245-53, viii. PubMed ID: 17430761 [TBL] [Abstract][Full Text] [Related]
19. Life-threatening acute adverse cutaneous drug reactions. Wolf R; Orion E; Marcos B; Matz H Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211 [TBL] [Abstract][Full Text] [Related]
20. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. Todd G Dermatol Clin; 2006 Oct; 24(4):459-72, vi. PubMed ID: 17010776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]